

SÃ©bastien Anguille

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3330082/publications.pdf>

Version: 2024-02-01

45
papers

2,623
citations

236925

25
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

3964
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical use of dendritic cells for cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, e257-e267.	10.7	565
2	Induction of complete and molecular remissions in acute myeloid leukemia by Wilmsâ€™ tumor 1 antigen-targeted dendritic cell vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13824-13829.	7.1	341
3	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <i>Blood</i> , 2017, 130, 1713-1721.	1.4	170
4	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. , 2016, 158, 24-40.		158
5	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2015, 67, 731-753.	16.0	129
6	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. <i>Journal of Hematology and Oncology</i> , 2016, 9, 101.	17.0	96
7	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 164.	17.0	88
8	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. <i>Blood</i> , 2012, 120, 3936-3944.	1.4	80
9	Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. <i>Journal of Translational Medicine</i> , 2009, 7, 109.	4.4	74
10	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. <i>Frontiers in Immunology</i> , 2019, 10, 1613.	4.8	70
11	Dendritic Cell-Based Cancer Gene Therapy. <i>Human Gene Therapy</i> , 2009, 20, 1106-1118.	2.7	68
12	Tumoricidal activity of human dendritic cells. <i>Trends in Immunology</i> , 2014, 35, 38-46.	6.8	62
13	Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e1021538.	4.6	53
14	Dendritic cell vaccination in acute myeloid leukemia. <i>Cytotherapy</i> , 2012, 14, 647-656.	0.7	49
15	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 579.	2.4	48
16	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. <i>PLoS ONE</i> , 2012, 7, e51851.	2.5	48
17	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. <i>PLoS ONE</i> , 2015, 10, e0123340.	2.5	47
18	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. <i>Pharmaceutics</i> , 2020, 12, 194.	4.5	40

#	ARTICLE	IF	CITATIONS
19	Transpresentation of interleukin-15 by IL-15/IL-15R α mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. <i>Oncotarget</i> , 2015, 6, 44123-44133.	1.8	39
20	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. <i>Frontiers in Immunology</i> , 2018, 9, 658.	4.8	38
21	Interferon α may be back on track to treat acute myeloid leukemia. <i>Oncolmmunology</i> , 2013, 2, e23619.	4.6	33
22	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. <i>PLoS ONE</i> , 2011, 6, e20952.	2.5	31
23	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. <i>Hum Vaccin</i> , 2011, 7, 579-584.	2.4	30
24	CD56 marks human dendritic cell subsets with cytotoxic potential. <i>Oncolmmunology</i> , 2013, 2, e23037.	4.6	29
25	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1956-1961.	3.3	28
26	Engineering monocyte-derived dendritic cells to secrete interferon- α enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	4.2	27
27	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	4.4	21
28	The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. <i>Pharmaceutics</i> , 2021, 13, 396.	4.5	18
29	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. <i>Oncotarget</i> , 2017, 8, 13652-13665.	1.8	18
30	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. <i>Oncotarget</i> , 2016, 7, 73960-73970.	1.8	17
31	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV α -positive tumour cells. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 1372-1380.	3.6	16
32	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. <i>Cancers</i> , 2019, 11, 1396.	3.7	13
33	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. <i>Cancers</i> , 2020, 12, 256.	3.7	12
34	CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucl, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy. <i>Blood</i> , 2021, 138, 2910-2910.	1.4	11
35	Biological correlative analyses and updated clinical data of ciltacabtagene autoleucl (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8029-8029.	1.6	11
36	Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. <i>Journal of Clinical Medicine</i> , 2020, 9, 3090.	2.4	8

#	ARTICLE	IF	CITATIONS
37	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. <i>Cancers</i> , 2019, 11, 1029.	3.7	7
38	Generation and Cryopreservation of Clinical Grade Wilmsâ€™ Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2016, 1393, 27-35.	0.9	6
39	Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	1.4	6
40	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. <i>Blood</i> , 2014, 124, 310-310.	1.4	5
41	Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2801-2814.	4.2	3
42	Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4519.	3.7	2
43	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. <i>Frontiers in Immunology</i> , 2022, 13, 734256.	4.8	2
44	Identification of a hypertrophied bronchial artery using three-dimensional computed tomography. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 764-764.	1.4	1
45	Sore throat: a trivial complaint masking a lifeâ€threatening condition. <i>Medical Journal of Australia</i> , 2009, 190, 454-456.	1.7	0